Julieta Politi, Juan‐Miguel Guerras, Marta Donat, María J. Belza, Elena Ronda, Gregorio Barrio, Enrique Regidor – 11 November 2021

To introduce artificial intelligence in the management of liver disease for clinicians. This program spans several applications of AI in hepatology spanning administrative datasets, radiology, pathology and multi-omics. This interactive session will spur further dialogue and research into this field and provide a platform to build on for future CRW events.

The 2021 AASLD/ASGE Endoscopy Course at AASLD will foster discussions on the management of challenging clinical scenarios encountered by hepatologists and gastroenterologists that require endoscopic consideration. This evidence-based course includes expert opinions on potential knowledge gaps or clinical controversies. The session has a case-based, interactive format that emphasizes good clinical practice, emerging paradigms, innovation, and safety concerns.

What pressing challenges do patients with advanced liver disease and/or liver cancer face as they consider treatment options with their physicians? Complex diseases must be managed by a multidisciplinary team to achieve optimal outcomes. At this program, faculty will review effective strategies to incorporate multidisciplinary approaches in the management of liver cancer, portal hypertension, and substance-use disorders.

Hepatocellular carcinoma (HCC) management strategies have been revolutionized over the last five years. Combination therapies are now standard of care for advanced HCC patients, and novel emerging therapies are currently being tested and approved. At this exciting talk, experts will review the many opportunities to improve management, quality of life and outcomes of patients with advanced HCC.

Precision medicine in NAFLD may be within reach due to exciting advances in AI technology and genomics. At this year’s NAFLD SIG program, renowned experts share new insights on precision medicine for NAFLD, including recent trends and developments in NAFLD genomics and transcriptomics, and advances in artificial intelligence for NAFLD diagnosis.

Available, safe, and effective oral antiviral therapies help manage complications in patients with HBV, who are at increased risk for infection reactivation as they age due to increased exposure to biologics for various comorbidities. Experts will share advances in novel diagnostic and prognostic biomarkers, when hepatologists should consider prophylactic antiviral therapy, and research advances toward an HBV cure.

Now is the time to discuss transplant metrics and policies, and strategies to improve them in the modern era to drive better long-term, patient-reported outcomes. As liver grafts are still a scarce resource, it is critical to maximize graft utilization and patient survival. This timely program will explore the most recent data to help hepatologists achieve this critical goal.

Implementing up-to-date AASLD practice guidance statements and recommendations can positively affect treatment decisions and patient outcomes at a time when selecting optimal therapy remains a challenge. Review best practices for diagnosis and treatment of patients with nutrition, sarcopenia & frailty, Wilson disease, and primary sclerosing cholangitis-cholangiocarcinoma, plus palliative care in end-stage liver disease and efficacy of noninvasive liver disease assessments.

The 2021 Emerging Trends Symposium will focus on strategies to tailor NASH therapy to the individual patient. Faculty will discuss different phenotypes of NAFLD/NASH, including from a genetic and non-invasive testing perspective. Talks will also cover evidence-based management of NAFLD/NASH and obesity, including lifestyle management discussions with patients, and emerging therapies and noninvasive testing options.